SBIR/STTR Research Award

A NOVEL SELF-ASSEMBLING PROTEIN NANOPARTICLES-BASED GENITAL HERPES VACCINE

Award identifier dd70412004f5faa38974a0a5ea5bbaa7f94e98688c7b05c803a77aeb676e30fdAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$235,980

Program and phase

STTR · Phase I

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Sunomix Therapeutics
Proposal award date
2018-04-01
Contract end date
2019-03-31
UEI
FCKXY3WV5R26
Solicitation number
PA17-303
Topic code
NIAID

Research abstract

ABSTRACTA staggering number of overbillion individuals worldwide are currently infected with herpes simplex virus typeand or typeHSVandampHSVwhich cause genital herpesMost HSV seropositive individuals are asymptomaticASYMPand never have any recurrent herpetic diseaseIn contrasta small proportion is symptomaticSYMPwith frequentoften lifelong bouts of recurrent herpetic diseasea result of reactivation of latent HSV from sensory neurons of the dorsal root gangliaDRGOur long term goal is to develop a vaccine to protect against genital herpesThe most recent vaccine clinical trials that used a recombinant HSVglycoprotein DgDbased subunit antigen vaccine mixed with monophosphoryl lipid AMPLAAdjuvant and delivered intramuscularlyThis gDantigen delivery system failed to protect despite inducing strong HSVspecific neutralizing antibodiesThis emphasizes two major gaps in knowledgeThe need to design an alternative antigen delivery system that will induce cell mediated immune responsesin addition to humoral responsesThe need to design HSV vaccines that will include T cell epitopes from HSV antigensAgsother than gDand or T cell epitopesA critical role for HSV specific sensory ganglia resident CDT cells in aborting reactivation of latent HSV has been establishedand the involvement of vaginal mucosaVMresident CDT cells is gaining wider acceptanceOur recent published and preliminary data demonstrate thatACDT cells fromnaturally protectedHSV seropositive ASYMP individuals mainly recognize CDT cell epitopes from HSV tegument protein ULVPBImmunization of Bmice with Self Assembling Protein NanoparticlesSAPNsthat incorporate an HSV CDT cell epitope together with a CDT helper epitope and flagellin CpGadjuvants induced strong and long lasting CDT cell responses and protected against genital herpesBuilding on the above published and preliminary datawe hypothesize that a SAPNsbased antigen delivery system and that incorporates human CDand CDT cell epitopesrecently identified in our lab from the ULtegument proteincan boost the number and or function of protective DRG resident CDand CDT cells and prevent or reduce genital herpesTo test this hypothesiswe proposesynergistic Specific AimsAimTo test the hypothesis that intravaginal immunization of HLA double transgenic mice with selfSAPNs based herpes vaccines incorporating single pairs of human CDand CDT cell epitopes identified from HSVULVPtegument protein will induce vaginal mucosaVMand DRG resident CDand CDT cells and protect against genital herpesAimTest the hypothesis that intravaginal immunization of HLA double transgenic mice with a SAPNs based herpes vaccine incorporating multiple human ULCDand CDT cell epitopes instring of pearlswill induce vaginal mucosaVMand DRG resident CDand CDT cells and protect against genital herpesSuccessful completion of the proposed work should help build a strong foundation toward developing an effective SAPNs based genital herpes vaccine PROJECT NARRATIVE Genital herpes diseasecaused by HSVand HSVinfectionsis a major global health problemThis proposal will pre clinically test a novel Self Assembling Protein NanoparticlesSAPNsbased genital herpes vaccinethat incorporate recently identified human CDand CDT cell epitopes from the HSV ULtegument proteininhumanizedHLA Tg mouse model of genital herpesResults from this pre clinical study will pave the way toward developing a novel SAPNs based genital herpes vaccine for clinical application

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

2 SBIR/STTR records share this UEI (2018–2022). Reported award amounts total $487,990. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.